AAV gene therapy for STXBP1 and SYNGAP1 encephalopathies
BS, Biology, The Ohio State University
Princeton Junction
Hiking/backpacking, running, camping, fishing, soccer, art, music/concerts, reading, woodworking, travel
Gene Therapy for neurodegenerative diseases, neuronal circuits/networks
MD, UNAM Mexico
PhD, UNAM Mexico
Mexico City
Oxford, UK
Traveling, cooking, hiking
Neurotrauma, neuroplasticity, spinal cord circuitry, gene therapies
BS, Kinesiology, Indiana University
MS, Kinesiology, Indiana University
PhD, Translational Neurosciences, University of Louisville
Valparaiso, Indiana
Tennis, hiking, American whiskey/bourbon
Dr Davidson is the Director of Translational Research at ENDD, the Chief Scientific Strategy Officer and Director of the Raymond G. Perelman Center for Cellular and Molecular Therapeutics and the Arthur V. Meigs endowed Chair in Pediatrics at the Children’s Hospital of Philadelphia. She is also Professor of Pathology and Laboratory Medicine and Professor of Genetics at the Perelman School of Medicine, University of Pennsylvania.
In 2019, Dr Davidson was elected a member of the National Academy of Medicine for her “being on the forefront of developing innovative therapies and medicines for fatal, inherited brain disorders, which are engineered to either remove toxic proteins or replace missing proteins, and for improving or preventing disease progression.”
Dr Davidson received her B.S. in Biology from Nebraska Wesleyan University, and Ph.D. in Biological Chemistry from University of Michigan. She completed postdoctoral studies in Molecular Genetics at the University of Michigan. Recent honors include election into the American Academy of Arts. She is the current president of the American Society of Gene and Cell Therapy, the largest international association of gene and cell therapy research.